Halozyme Therapeutics Inc
HALO
Company Profile
Business description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Contact
12390 El Camino Real
San DiegoCA92130
USAT: +1 858 794-8889
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
350
Stocks News & Analysis
stocks
Weekly Earnings Wrap: CBA, CSL, MQG and more
Everything you need to know on last weeks earnings results
stocks
ASX player rallies on small guidance upgrade
Our fair value is maintained despite investor enthusiasm.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.80 | 66.60 | -0.72% |
| CAC 40 | 8,300.32 | 40.24 | -0.48% |
| DAX 40 | 24,866.68 | 13.99 | 0.06% |
| Dow JONES (US) | 49,389.11 | 62.87 | -0.13% |
| FTSE 100 | 10,412.24 | 9.80 | 0.09% |
| HKSE | 26,567.12 | 465.42 | -1.72% |
| NASDAQ | 22,543.89 | 53.26 | -0.24% |
| Nikkei 225 | 56,941.97 | 697.87 | -1.21% |
| NZX 50 Index | 13,198.18 | 333.30 | -2.46% |
| S&P 500 | 6,829.92 | 2.84 | -0.04% |
| S&P/ASX 200 | 8,917.60 | 55.30 | -0.62% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |